Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Outcomes,Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab. A Multicenter Post-Marketing Observational Study in Routine Clinical Use

NCT01083160 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT01083160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01083160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Outcomes,Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab. A Multicenter Post-Marketing Observational Study in Routine Clinical Use
Lead sponsor
Abbott
Phase
Observational
Overall status
Terminated
Start date
April 30, 2008
Completion date
November 30, 2010
Enrollment
82 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis